These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 620951)

  • 1. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
    Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II clinical trial of VP-16-213 in ovarian cancer.
    Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
    Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
    Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
    Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
    Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW
    Tumori; 1977; 63(2):169-73. PubMed ID: 898287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
    J Natl Cancer Inst; 1977 Dec; 59(6):1619-20. PubMed ID: 579188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
    Suzuki K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
    Slayton RE; Creasman WT; Petty W; Bundy B; Blessing JA
    Cancer Treat Rep; 1979; 63(11-12):2089-92. PubMed ID: 526942
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
    Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
    Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
    [No Abstract]   [Full Text] [Related]  

  • 10. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
    Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
    Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral etoposide in gestational trophoblastic disease.
    Wong LC; Choo YC; Ma HK
    Cancer Treat Rep; 1984 May; 68(5):775-7. PubMed ID: 6327035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
    Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
    Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
    Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M
    Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845
    [No Abstract]   [Full Text] [Related]  

  • 16. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
    Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
    Kimura K; Yamada K; Yoshida T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 19. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
    Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.